Monte Rosa Therapeutics (GLUE) said Monday that the first patients have been dosed in its phase 1 study of MRT-8102 for the treatment of multiple inflammatory diseases.
The study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of the drug in healthy volunteers, the company said.
Monte Rosa said it expects the initial results of the study in H1 of 2026.
The company's shares were up 6.2% in premarket activity on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.